Alpha 2.0
Login Register
» Articles » PMID: 29127081

Should Cost Effectiveness Analyses for NICE Always Consider Future Unrelated Medical Costs?

Overview
Journal BMJ
Specialty General Medicine
Date 2017 Nov 12
PMID 29127081
Citations 11
Authors
Pieter van Baal
Alec Morton
Werner Brouwer
David Meltzer
Sarah Davis
Affiliations
Soon will be listed here.
Citing Articles

Context-Specific Estimation of Future Unrelated Medical Costs and Their Impact on Cost-Effectiveness Analyses.

Epstein N, Simon-Tuval T, Berchenko Y Pharmacoeconomics. 2023; 41(10):1275-1286.

PMID: 37329391 DOI: 10.1007/s40273-023-01290-7.

Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations.

Otten T, Grimm S, Ramaekers B, Joore M Pharmacoeconomics. 2023; 41(6):619-632.

PMID: 36943674 PMC: 10163110. DOI: 10.1007/s40273-023-01242-1.

Future Offspring Costs in Economic Evaluation.

Verbeke E, Luyten J Pharmacoeconomics. 2021; 40(2):141-147.

PMID: 34713421 DOI: 10.1007/s40273-021-01102-w.

Incorporating future unrelated medical costs in cost-effectiveness analysis in China.

Jiang S, Wang Y, Zhou J, Jiang Y, Liu G, Wu J BMJ Glob Health. 2021; 6(10).

PMID: 34702751 PMC: 8549663. DOI: 10.1136/bmjgh-2021-006655.

The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS.

Perry-Duxbury M, Lomas J, Asaria M, van Baal P Pharmacoeconomics. 2021; 40(2):233-239.

PMID: 34697717 PMC: 8545559. DOI: 10.1007/s40273-021-01090-x.